Your browser doesn't support javascript.
loading
Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies.
Zhang, Chaoting; Palashati, Heyilimu; Rong, Zhuona; Lin, Ningjing; Shen, Luyan; Liu, Ying; Li, Shance; Yu, Bentong; Yang, Wenjun; Lu, Zheming.
Afiliación
  • Zhang C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Palashati H; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Rong Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Lin N; Key Laboratory of Carcinogenesis and Translational Research, Departments of Lymphoma, Radiology and Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
  • Shen L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Liu Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Li S; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Yu B; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China. yubentong@126.com.
  • Yang W; Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Jiangxi, 330006, China. yubentong@126.com.
  • Lu Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China. ywj007@yeah.net.
Mol Cancer ; 19(1): 162, 2020 11 21.
Article en En | MEDLINE | ID: mdl-33218364
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos T / Linfocitos T / Leucemia de Células T / Inmunoterapia Adoptiva / Depleción Linfocítica / Citotoxicidad Inmunológica Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos T / Linfocitos T / Leucemia de Células T / Inmunoterapia Adoptiva / Depleción Linfocítica / Citotoxicidad Inmunológica Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: China